Portola Pharmaceuticals Presents New In Vitro Data | PTLA Message Board Posts

Portola Pharmaceuticals, Inc.

  PTLA website

PTLA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  6373 of 6517  at  7/9/2019 7:01:14 AM  by

JoeFlow


 In response to msg 6372 by  tjinvest
view thread

Re: Portola Pharmaceuticals Presents New In Vitro Data

 "But from this PR, we now know maybe 25% of the "potential Andexxa patients" have levels < 75 ng/ml, and might be effectively treated with KCentra."
 
first off, total patients in this "study" is very small, n=10.  Do you think those results will lead to a large clinical trial to determine if these results are even statistically significant?  Second, do you think physicians will wait for test results of FXa inhibitor levels in patients admitted with uncontrolled bleeding known to be on NOACs.  that is extremely unlikely...
 
this is good news for PTLA. 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 8     Views: 384
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
6374 Re: Portola Pharmaceuticals Presents New In Vitro Data tjinvest 4 7/9/2019 11:55:31 AM


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...